Date: 2016-05-09
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at The European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London
Company: Prothena (Ireland)
Product: PRX003
Action
mechanism: monoclonal antibody. PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule (MCAM), believed to be a critical mediator of Th17 cell pathogenesis, for the potential treatment of inflammatory diseases where multiple cytokines play a role. As MCAM expressing T cells appear to be disproportionately involved in propagation of inflammation, targeting the T cell, rather than any individual cytokine, may provide a highly specific way to impact multiple pathogenic processes, while leaving the vast majority of immune cells unaffected. PRX003 may be useful for the treatment of a variety of inflammatory diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, sarcoidosis, uveitis, giant cell arteritis, and Behcet's disease.
Disease: psoriasis
Therapeutic area: Autoimmune diseases - Dermatological diseases
Country: USA
Trial
details: This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 56 patients with psoriasis. (NCT02630901 )
Latest
news: * On May 9, 2016, Prothena Corporation announced that clinical data from its Phase 1 single ascending dose study of PRX003 in healthy volunteers will be highlighted in an oral presentation at The European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London. The PRX003 Phase 1 clinical data will be highlighted in the following oral presentation:
Session #EULAR16-3570, Abstract #OP0205
Clinical and Preclinical Assessment of the Anti-MCAM Monoclonal Antibody PRX003, a Potential Novel Treatment of Th17-mediated Inflammatory Diseases. Presenter: Gene Kinney, PhD, Chief Scientific Officer and Head of Research and Development, Prothena.
